Containing PDE 4 inhibitor as active component and polyvinylpyrrolidone as the peroral dosage form of excipient

Containing PDE 4 inhibitor as active component and polyvinylpyrrolidone as the peroral dosage form of excipient

  • CN 102,764,242 B
  • Filed: 02/19/2003
  • Issued: 09/07/2016
  • Est. Priority Date: 02/20/2002
  • Status: Active Grant
First Claim
Patent Images

1. , for tablet or the formulation of pill of oral administration sl. sol. PDE 4 inhibitor, it comprises sl. sol. PDE 4 and presses downPreparation and polyvinylpyrrolidone, and one or more other suitable drug excipients, wherein said PDE 4 inhibitor is N-(3,5-dichloropyridine-4-base)-3-cyclo propyl methoxy-4-difluoromethoxybenzoamine amine (roflumilast), and wherein saidFormulation is the solid oral dosage form (discharging solid oral dosage form immediately) of release of active ingredients immediately, and wherein said formulation every doseAmount unit contains 0.1 mg, 0.125 mg, 0.25 mg or the roflumilast of 0.5 mg.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×